AU Patent

AU2025205010A1 — Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Assigned to AbbVie Inc · Expires 2025-07-24 · 1y expired

What this patent protects

#$%^&*AU2025205010A120250724.pdf##### PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4- (3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABSTRACT The present disclosure relates to processes …

USPTO Abstract

#$%^&*AU2025205010A120250724.pdf##### PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4- (3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABSTRACT The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2- a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by- process. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4- (3H-IMIDAZO[1,2-]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABSTRACT The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2- a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrolidine-1-carboxamide,solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by- process. 20 25 20 50 10 01 J ul 2 02 5 P R O C E S S E S F O R T H E P R E P A R A T I O N O F ( 3 S , 4 R ) - 3 - E T H Y L - 4 - ( 3 H - I M I D A Z O [ 1 , 2 - q ] P Y R R O L O [ 2 , 3 - p ] - P Y R A Z I N - 8 - Y L ) - N - ( 2 , 2 , 2 - T R I F L U O R O E T H Y L ) P Y R R O L I D I N E - 1 - C A R B O X A M I D E A N D 2 0 2 5 2 0 5 0 1 0 0 1 J u l 2 0 2 5 S O L I D S T A T E F O R M S T H E R E O F A B S T R A C T T h e p r e s e n t d i s c l o s u r e r e l a t e s t o p r o c e s s e s f o r p r e p a r i n g ( 3 S , 4 R ) - 3 - e t h y l - 4 - ( 3 H - i m i d a z o [ 1 , 2 - a ] p y r r o l o [ 2 , 3 - e ] p y r a z i n - 8 - y l ) - N - ( 2 , 2 , 2 - t r i f l u o r o e t h y l ) p y r r o l i d i n e - l - c a r b o x a m i d e , s o l i d s t a t e f o r m s t h e r e o f , a n d c o r r e s p o n d i n g p h a r m a c e u t i c a l c o m p o s i t i o n s , m e t h o d s o f t r e a t m e n t ( i n c l u d i n g t r e a t m e n t o f r h e u m a t o i d a r t h r i t i s ) , k i t s , m e t h o d s o f s y n t h e s i s , a n d p r o d u c t s - b y - p r o c e s s .

Drugs covered by this patent

Patent Metadata

Patent number
AU2025205010A1
Jurisdiction
AU
Classification
Expires
2025-07-24
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.